KR100555653B1 - Composition comprising an extract of processed Panax genus plant for preventing and treating anxiety - Google Patents
Composition comprising an extract of processed Panax genus plant for preventing and treating anxiety Download PDFInfo
- Publication number
- KR100555653B1 KR100555653B1 KR1020030070249A KR20030070249A KR100555653B1 KR 100555653 B1 KR100555653 B1 KR 100555653B1 KR 1020030070249 A KR1020030070249 A KR 1020030070249A KR 20030070249 A KR20030070249 A KR 20030070249A KR 100555653 B1 KR100555653 B1 KR 100555653B1
- Authority
- KR
- South Korea
- Prior art keywords
- panax
- ginseng
- extract
- anxiety
- processed
- Prior art date
Links
- 241000208343 Panax Species 0.000 title claims abstract description 39
- 235000002791 Panax Nutrition 0.000 title claims abstract description 37
- 239000000284 extract Substances 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title abstract description 34
- 208000019901 Anxiety disease Diseases 0.000 title abstract description 15
- 230000036506 anxiety Effects 0.000 title abstract description 14
- 241000196324 Embryophyta Species 0.000 title abstract description 12
- 235000008434 ginseng Nutrition 0.000 claims abstract description 69
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 62
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 61
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 16
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 13
- 239000002249 anxiolytic agent Substances 0.000 claims abstract description 8
- 206010002869 Anxiety symptoms Diseases 0.000 claims abstract description 3
- 240000004371 Panax ginseng Species 0.000 claims description 68
- 235000002789 Panax ginseng Nutrition 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002034 butanolic fraction Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 244000131316 Panax pseudoginseng Species 0.000 claims description 4
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 241000168720 Panax japonicus Species 0.000 claims description 3
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 3
- 241000180649 Panax notoginseng Species 0.000 claims description 3
- 241001527087 Panax vietnamensis Species 0.000 claims description 3
- 235000017726 Panax vietnamensis Nutrition 0.000 claims description 3
- 241000180664 Panax wangianus Species 0.000 claims description 3
- 235000003138 Panax wangianus Nutrition 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000000049 anti-anxiety effect Effects 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 6
- 238000012545 processing Methods 0.000 abstract description 4
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 229940089161 ginsenoside Drugs 0.000 abstract description 3
- 241000208340 Araliaceae Species 0.000 abstract description 2
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 17
- 235000013361 beverage Nutrition 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 239000000419 plant extract Substances 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000012454 non-polar solvent Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000012223 aqueous fraction Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- -1 anti-stress Substances 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241001625498 Polyscias elegans Species 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical group C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004069 plant analysis Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 약효가 증강된 파낙스속 식물의 가공 추출물을 함유하는 불안증세의 예방 및 치료를 위한 조성물에 관한 것으로, 본 발명에 의한 인삼을 진세노사이드 (Rg3 + Rg5 + Rk1)/(Rb1 + Rb2 + Rc + Rd)의 비율이 1.0이상이 되도록 특수가공처리하여 수득한 인삼 추출물은 항불안 효과가 탁월하여, 불안증세의 예방 및 치료에 유용한 약제 및 건강기능식품으로 이용할 수 있다.The present invention relates to a composition for the prevention and treatment of anxiety, containing a processed extract of Panax genus plants with enhanced efficacy, ginsenoside (Rg3 + Rg5 + Rk1) / (Rb1 + Rb2) The ginseng extract obtained by special processing so that the ratio of + Rc + Rd) is 1.0 or more is excellent in anti-anxiety effect, and can be used as a pharmaceutical and health functional food useful for the prevention and treatment of anxiety symptoms.
파낙스속, 인삼, 항불안, 추출물, 조성물, 약제, 건강기능식품.Panax genus, ginseng, anti-anxiety, extracts, compositions, pharmaceuticals, dietary supplements.
Description
도 1 은 백삼과 특수가공인삼의 항불안효과 비교한 것으로, 오픈 암에 들어간 횟수를 나타낸 도이고,1 is a comparison of the anti-anxiety effect of white ginseng and special processed ginseng, showing the number of times the open cancer entered,
도 2 는 백삼과 특수가공인삼의 항불안효과 비교한 것으로, 오픈 암에 머문 시간을 나타낸 도이고,Figure 2 is a comparison of the anti-anxiety effect of white ginseng and special processed ginseng, showing the time spent in open cancer,
도 3 은 특수가공인삼의 분획별 약효 비교한 것으로 오픈 암에 들어간 횟수를 나타낸 도이고,Figure 3 is a diagram showing the number of times entered into the open cancer to compare the efficacy of the fraction of special processed ginseng,
도 4 는 특수가공인삼의 분획별 약효 비교한 것으로 오픈 암에 머문 시간을 나타낸 도이다.Figure 4 is a diagram showing the time spent in open cancer to compare the efficacy of each fraction of special processed ginseng.
본 발명은 약효가 증강된 파낙스속 식물의 가공 추출물을 함유하는 항불안제 에 관한 것이다.The present invention relates to an anti-anxiety agent containing a processed extract of the genus Panax plant with enhanced efficacy.
많은 사람들이 정서적 압박감(stress)이나 불안(anxiety) 상태를 경험하지만 그 기간이 짧고 가벼워서 약물처치가 불필요하나 때때로 불안증상이 일의 수행에 지장을 초래하기도 한다. 또한 불안 증상이 심해지면 정신질환징후를 나타내기도 한다. 불안 증상을 가진 사람은 겁먹음(panic), 걱정(worry), 긴장(tension), 놀램(startle), 공포(phobia)등이 정상인보다 증가되어 나타난다. 진정제는 불안의 증후를 완화시키는 약이다. 특히 벤조디아제핀(benzodiazepine)류는 가장 많이 사용되는 항불안제(anxiolytic)인데, 부스피론(buspirone, 세로토닌 효능약) 등이 알려져 있다. 그러나 이러한 약물은 불안을 치료하는데 사용되는 약물들로 부작용이 강하여 초조감 등 가벼운 불안을 경험하는 수험생, 자신감이 결여된 스포츠맨, 그리고 과도한 스트레스에 시달리는 비즈니스맨 등에게 사용하기에는 부적합하다. 따라서 이들에게 부작용이 없으면서 불안을 극복할 수 있는 물질을 개발하는 일이 매우 중요하다. Many people experience emotional stress or anxiety, but the duration is short and light, so medication is unnecessary, but sometimes anxiety can interfere with work. In addition, symptoms of anxiety may cause symptoms of mental illness. People with anxiety are more likely to have panic, worry, tension, startle, and phobia than normal people. Sedatives are medicines that alleviate the symptoms of anxiety. In particular, benzodiazepines are the most used anti-anxiety agents (anxiolytic), such as buspirone (serotonin agonist) is known. However, these drugs are used to treat anxiety, so they are not suitable for those who have mild anxiety such as nervousness, sportsmen who lack confidence, and businessmen who suffer from excessive stress. Therefore, it is very important to develop materials that can overcome anxiety without side effects.
인삼은 파낙스(Panax)속에 속하는 다년생 식물로, 파낙스속 식물은 식물 분류학상 오가과(Araliaceae)에 속하는 다년생 숙근초로서 지구상에 십여 종이 알려져 있다. 대표적인 종으로 고려인삼(Panax ginseng), 화기삼(Panax quinquefolia), 전칠삼(삼칠, Panax notoginseng), 죽절삼(Panax japonica), 삼엽삼 (Panax trifolia), 히말라야삼 (Panax pseudoginseng), 베트남삼 (Panax vietnamensis) 등이 있다 (고려삼의 이해, 9쪽, 고려인삼학회, 1995년; Advances in Ginseng Research, 127-137쪽, 고려인삼학회, 1998). 기타 파낙스속 식물로는 파낙스 엘레 가티오르(Panax elegatior), 파낙스 완지아누스(Panax wangianus), 파낙스 비핀라티푸스(Panax bipinratifidus) 등이 있다.Ginseng is a perennial plant belonging to the genus Panax, and the genus Panax is a perennial root of the genus Araliaceae. Representative species include Panax ginseng , Panax quinquefolia , Panax ginseng , Panax notoginseng , Panax japonica , Panax trifolia , Panax pseudoginseng , and Panax vietnamensis. (Understanding Korea Ginseng, p. 9, Korea Ginseng Society, 1995; Advances in Ginseng Research, pp. 127-137, Korea Ginseng Society, 1998). Other Panax genus plants include Panax elegans Gatti climb (Panax elegatior), Panax Wan Jia Taunus (Panax wangianus), Panax non pinra typhus (Panax bipinratifidus).
이러한 파낙스속 식물에서 가장 중요한 성분은 사포닌이다. 특히 파낙스속 식물에는 다른 식물과는 다른 담마란(dammarane) 골격에 1-4개의 당이 결합되어 있는 사포닌을 공통으로 함유하고 있다. 특히 고려인삼에 함량이 높은 사포닌은 진세노사이드 Rb1, Rb2, Rc, Rd, Rg1, Re 등이다. 이러한 사포닌 성분들은 다양한 약효를 나타내는데 그 구조에 따라 약효의 종류와 강도가 매우 다르다(고려삼의 이해, 고려인삼학회, 1995년).The most important component in these Panax plants is saponin. In particular, the Panax genus contains a common saponin in which 1-4 sugars are bound to a dammarane skeleton unlike other plants. In particular, saponins with high content in Korean ginseng are ginsenosides Rb1, Rb2, Rc, Rd, Rg1 and Re. These saponin components show various effects, and the types and strengths of the drugs vary greatly depending on their structure (Understanding Goryeo Ginseng, Korea Ginseng Society, 1995).
예로부터 인삼은 피로회복이나 정력증강에 유효하다고 알려져 있다. 실제적으로 인삼은 탐색활동의 증가, 자발운동의 감소, 경련 역치의 상승, 기억력 증가, 진통효과 등이 있는 것으로 알려져 있다(고려삼의 이해, 고려인삼학회, 1995년). 또한 이러한 효과 외에도 불안신경증, 불면, 우울증상, 산전산후의 정신증상 개선에도 적용되어 왔다(생약학, 학창사, 2003년)Ginseng has long been known to be effective for fatigue recovery and strength enhancement. In fact, ginseng is known to have increased exploratory activity, decreased spontaneous exercise, increased seizure threshold, increased memory, and analgesic effects (Understanding Korean Ginseng, Korea Ginseng Society, 1995). In addition to these effects, it has been applied to improvement of anxiety neurosis, insomnia, depression, and postpartum psychiatric symptoms (herbal medicine, Hakchangsa, 2003).
그러나 인삼의 이러한 약효는 매우 미약하다는 단점이 있다. 최근 인삼에 여러 가공법을 적용하여 인삼의 약효를 강화시키려는 시도가 있었다. 그 중 가장 대표적인 방법은 박 등이 개발한 방법이다. 박 등은 인삼을 고온 고압 조건에서 특수 가공하는 방법을 개발하였다(대한민국특허 제192678호, 미국특허 제5776460호). 이러한 가공과정에서 원래 인삼에 주로 함유되어 있는 사포닌 성분인 진세노사이드 Rb1, Rb2, Rc, Rd가 원래 인삼에는 없는 진세노사이드 Rg3, Rg5, Rk1 으로 변하고 또한 여러 가지 새로운 약효성분이 생성되어 항산화작용, 항암작용, 혈액순환개선 작용 등이 매우 강화된다(김 등, Journal of Natural Products, 63권, 1702-1704쪽, 2000년; 권 등, Journal of Chromatography A, 921권, 335-339쪽, 2001년). 특히 Rg3, Rg5, Rk1의 약효가 강한 것으로 알려져 있는데, 그러나 아직까지 이들 성분이나 이렇게 특수 가공된 인삼의 항불안효과에 대하여는 연구된 바가 없다.However, the ginseng's effect is very weak. Recently, there have been attempts to enhance the efficacy of ginseng by applying various processing methods to ginseng. The most representative method is the method developed by Park et al. Park et al. Developed a method of specially processing ginseng under high temperature and high pressure conditions (Korean Patent No. 192678, US Patent No. 5776460). In this process, ginsenosides Rb1, Rb2, Rc, and Rd, which are mainly contained in ginseng, are changed to ginsenosides Rg3, Rg5, and Rk1, which are not present in ginseng, and various new medicinal ingredients are produced to prevent antioxidant , Anticancer activity, and blood circulation improvement are greatly enhanced (Kim et al., Journal of Natural Products, Vol. 63, pp. 1702-1704, 2000; Vol. Et al., Journal of Chromatography A, vol. 921, pp. 335-339, 2001 year). In particular, the potency of Rg3, Rg5, Rk1 is known to be strong, but the anti-anxiety effect of these ingredients and specially processed ginseng has not been studied.
본 발명인들은 인삼을 특수 가공하여 진세노사이드 Rg3, Rg5, Rk1의 함량의 합이 진세노사이드 Rb1, Rb2, Rc, Rd의 함량의 합보다 더 많도록 한 특수가공인삼이 기존의 백삼보다 월등한 항불안효과가 있음을 확인하였고, 특히 Rg3, Rg5, Rk1을 함유하고 있는 분획이 효과가 강력함을 발견하여 본 발명을 완성하게 되었다.The present inventors processed ginseng specially processed ginseng so that the sum of the content of ginsenosides Rg3, Rg5, Rk1 is higher than the sum of the content of ginsenosides Rb1, Rb2, Rc, Rd is superior to conventional white ginseng. It was confirmed that there is an anti-anxiety effect, in particular, the fraction containing Rg3, Rg5, Rk1 was found to have a strong effect to complete the present invention.
따라서 본 발명의 목적은 파낙스속 식물을 특수가공하여 진세노사이드 (Rg3 + Rg5 + Rk1)/(Rb1 + Rb2 + Rc + Rd)의 비율이 1.0이상이 되도록 약효성분을 증가시킨 가공 파낙스속 식물의 추출물 및 분획의 항불안제, 항스트레스제, 항우울제로서의 용도를 제공하는 것이다.
Therefore, an object of the present invention is to process the Panax genus plants by specially processing the Panax genus plants to increase the active ingredient so that the ratio of ginsenosides (Rg3 + Rg5 + Rk1) / (Rb1 + Rb2 + Rc + Rd) is 1.0 or more It is to provide the use of the extracts and fractions as anti-anxiety, anti-stress, anti-depressant.
상기 목적을 달성하기 위하여, 본 발명은 진세노사이드 (Rg3 + Rg5 + Rk1)/(Rb1 + Rb2 + Rc + Rd)의 비율이 1.0이상이 되도록 약효성분을 증가시킨 가공 파낙스속 식물의 추출물을 함유하는 불안증상의 예방 및 치료용 조성물을 제공한다.In order to achieve the above object, the present invention contains an extract of the processed Panax genus plants in which the active ingredient is increased so that the ratio of ginsenosides (Rg3 + Rg5 + Rk1) / (Rb1 + Rb2 + Rc + Rd) is 1.0 or more. It provides a composition for preventing and treating anxiety symptoms.
단, 여기에서 Rg3는 (20-S)와 (20-R), 두가지 이성질체를 포함한다.Provided that Rg3 includes two isomers (20-S) and (20-R).
상기 가공파낙스속 식물은 120 내지 180℃의 고온에서 0.5 내지 20 시간동안 가열처리하여 제조될 수 있다.The processed Panax genus plants may be prepared by heat treatment at a high temperature of 120 to 180 ℃ for 0.5 to 20 hours.
또한, 상기 파낙스속 식물은 고려인삼(Panax ginseng), 미국삼(Panax quinquefolia), 전칠삼(삼칠, Panax notoginseng), 죽절삼(Panax japonica), 삼엽삼 (Panax trifolia), 히말라야삼 (Panax pseudoginseng), 베트남삼 (Panax vietnamensis), 파낙스 엘레가티오르(Panax elegatior), 파낙스 완지아누스(Panax wangianus), 또는 파낙스 비핀라티피두스(Panax bipinratifidus)의 전초, 뿌리, 줄기, 또는 잎 등의 식물을 포함한다.In addition, the genus Panax ginseng ( Panax ginseng ), American ginseng ( Panax quinquefolia ), ginseng (samchil, Panax notoginseng ), bamboo shoots ( Panax japonica ), trifolium ( Panax trifolia ), Himalayan ginseng ( Panax pseudoginseng ), Plants such as outposts, roots, stems, or leaves of Panax vietnamensis , Panax elegatior , Panax wangianus , or Panax bipinratifidus do.
상기 추출물은 물, C1 내지 C4의 저급알콜 및 이들의 혼합용매, 바람직하게는 70% 에탄올 또는 부탄올에 가용한 추출물을 의미한다.The extract refers to an extract soluble in water, lower alcohols of C1 to C4 and mixed solvents thereof, preferably 70% ethanol or butanol.
추가적으로, 본 발명은 진세노사이드 (Rg3 + Rg5 + Rk1)/(Rb1 + Rb2 + Rc + Rd)의 비율이 1.0이상이 되도록 약효성분을 증가시킨 가공파낙스속 식물의 비극성용매 가용 추출물을 함유하는 불안증상의 예방 및 치료용 조성물을 제공한다.In addition, the present invention is anxiety containing a non-solvent solvent soluble extract of the processed Panax genus plants with increased active ingredient so that the ratio of ginsenosides (Rg3 + Rg5 + Rk1) / (Rb1 + Rb2 + Rc + Rd) is 1.0 or more Provided are compositions for the prevention and treatment of symptoms.
상기 비극성 용매 가용 추출물은 헥산, 클로로포름, 메틸렌클로라이드, 에테르, 에틸아세테이트와 같은 비극성 용매, 보다 바람직하게는 에테르에 가용한 추출물을 의미한다.The non-polar solvent soluble extract means a non-polar solvent such as hexane, chloroform, methylene chloride, ether, ethyl acetate, more preferably an extract soluble in ether.
또한, 본 발명은 유효성분으로 진세노사이드 (20S)Rg3, (20R)Rg3, Rg5, Rk1 으로부터 선택된 하나 이상의 성분을 함유하는 항불안제를 제공한다.The present invention also provides an anti-anxiety agent containing at least one component selected from ginsenosides (20S) Rg3, (20R) Rg3, Rg5, and Rk1 as an active ingredient.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 가공파낙스속 식물 조추출물은, 건조된 가공인삼를 세절하여 무게(㎏)의 약 1배 내지 20배, 바람직하게는 약 3배 내지 10배의 물, C1 내지 C4의 저급 알콜 또는 이들의 혼합용매, 바람직하게는 70% 에탄올로, 20℃ 내지 100℃ , 바람직하게는 50℃ 내지 70℃ 추출온도에서 약 1시간 내지 10일, 바람직하게는 약 2시간 내지 5시간동안 냉침, 열수추출, 초음파 추출, 환류 냉각 추출방법을 이용하여 수득한 추출액을 여과, 감압농축 또는 동결건조하여 극성용매 가용추출물인 조추출물을 수득할 수 있다. The processed Panax genus plant crude extract of the present invention is chopped the dried processed ginseng, about 1 to 20 times the weight (kg), preferably about 3 to 10 times the water, C1 to C4 lower alcohol or their Mixed solvent, preferably 70% ethanol, cold soaking, hot water extraction, for about 1 hour to 10 days, preferably about 2 hours to 5 hours, at an extraction temperature of 20 ° C to 100 ° C, preferably 50 ° C to 70 ° C, The extract obtained by the ultrasonic extraction, reflux cooling extraction method is filtered, concentrated under reduced pressure or lyophilized to obtain a crude extract as a polar solvent soluble extract.
또한 본 발명의 비극성 용매 가용 추출물은 상기 조추출물을 증류수에 현탁한 후, 이를 현탁액이 약 1 내지 100배, 바람직하게는 약 1 내지 5배 부피의 헥산, 클로로포름, 메틸렌클로라이드, 에테르, 에틸아세테이트와 같은 비극성 용매를 가하여 1회 내지 10회, 바람직하게는 2회 내지 5회 비극성용매 가용층을 추출, 분리하여 수득할 수 있다. 또한 추가로 통상의 분획 공정을 수행할 수도 있다(Harborne J.B. Phytochemical methods: A guide to modern techniques of plant analysis. 3rd Ed. pp 6-7,1998). In addition, the non-polar solvent soluble extract of the present invention, after suspending the crude extract in distilled water, the suspension is about 1 to 100 times, preferably about 1 to 5 times the volume of hexane, chloroform, methylene chloride, ether, ethyl acetate and The same nonpolar solvent can be added to obtain a non-polar solvent soluble layer 1 to 10 times, preferably 2 to 5 times, to be obtained by extraction and separation. It is also possible to further carry out conventional fractionation processes (Harborne JB Phytochemical methods: A guide to modern techniques of plant analysis. 3rd Ed. Pp 6-7,1998).
본 발명의 바람직한 실시예에서는, 가공인삼을 70% 에탄올로 환류추출하여 조추출물을 수득하고, 이를 에테르로 추출하여 에테르 가용추출물 및 수가용추출물을 수득한 다음, 수가용추출물을 부탄올로 추출하여 부탄올분획물 및 수가용분획물을 수득한다.In a preferred embodiment of the present invention, the processed ginseng is refluxed with 70% ethanol to obtain a crude extract, which is extracted with ether to obtain an ether soluble extract and an aqueous extract, and then the aqueous extract is extracted with butanol. Fractions and aqueous fractions are obtained.
본 발명에 따른 가공인삼의 추출물을 마우스에 투여하여 항불안효과를 측정하였을 때, 가공인삼의 부탄올 분획물에서 유의성있는 항불안효과가 나타남을 확인 할 수 있었다.When the anti-anxiety effect was measured by administering the extract of the processed ginseng according to the present invention, it was confirmed that a significant anti-anxiety effect appeared in the butanol fraction of the processed ginseng.
본 발명의 파낙스속 식물 추출물을 포함하는 조성물은 통상의 방법에 따른 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The composition comprising Panax genus plant extract of the present invention may further comprise a suitable carrier, excipient and diluent according to conventional methods.
본 발명의 파낙스속 식물 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는, 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리쓰리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.Carriers, excipients and diluents that may be included in the composition comprising the Panax genus plant extract of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, Alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. .
본 발명에 따른 파낙스속 식물 추출물을 포함하는 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.Compositions comprising Panax genus plant extract according to the present invention, respectively, according to a conventional method of oral formulations, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injectable solutions It can be formulated and used in the form.
본 발명의 파낙스속 식물 추출물의 사용량은 환자의 나이, 성별, 체중에 따라 달라질 수 있으나, 0.1 내지 100mg/㎏의 양을 1일 1회 내지 수회 투여할 수 있다. 또한 그 파낙스속 식물 추출물의 투여량은 투여경로, 질병의 정도, 성별, 체중, 나이 등에 따라서 증감될 수 있다. 따라서, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The amount of Panax genus plant extract of the present invention may vary depending on the age, sex, and weight of the patient, but may be administered once to several times in an amount of 0.1 to 100 mg / kg. In addition, the dosage of the Panax genus plant extract may be increased or decreased depending on the route of administration, the severity of the disease, sex, weight, age, and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.
본 발명의 파낙스속 식물 추출물을 포함하는 조성물은 상기와 같은 제형으로 불안증세 관련 질환의 예방 및 치료를 위한 약제, 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 건강기능식품은 산제, 과립제, 정제, 캡슐제, 환제, 현탁 액, 에멀젼, 시럽, 에어로졸 등의 약학투여형태 또는 건강음료형태가 바람직하다. 본 파낙스속 식물 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다.The composition comprising the plant extract of Panax genus of the present invention can be used in various formulations, such as drugs, foods and beverages for the prevention and treatment of anxiety-related diseases in the above formulation. The health functional food of the present invention is preferably in the form of a pharmaceutical or health beverage such as powders, granules, tablets, capsules, pills, suspensions, emulsions, syrups, aerosols. Examples of the food to which the Panax genus plant extract can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.
본 발명의 파낙스속 식물 추출물 자체는 독성 및 부작용은 거의 없으므로 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있다.Panax genus plant extract of the present invention has little toxicity and side effects, so can be used with confidence even for long-term use for the purpose of prevention.
본 발명의 상기 파낙스속 식물 추출물은 불안 관련 질환의 예방을 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 파낙스속 식물 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02∼5 g, 바람직하게는 0.3∼1g의 비율로 가할 수 있다. Panax genus plant extract of the present invention may be added to food or beverage for the purpose of prevention of anxiety-related diseases. At this time, the amount of the Panax plant extract in the food or beverage may be added at 0.01 to 15% by weight of the total food weight, the health beverage composition is 0.02 to 5 g, preferably 0.3 to 1g based on 100 ml Can be added.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 ∼ 20g, 바람직하게는 약 5 ∼ 12g이다.The health functional beverage composition of the present invention is not particularly limited to other ingredients except for having the extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in general beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrate is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명은 다음의 실시예에 의거하여 더욱 상세히 설명되나, 본 발명이 이에 의해 제한되지는 않는다.The present invention is described in more detail based on the following examples, although the present invention is not limited thereto.
[실시 예 1] 특수가공인삼의 제조Example 1 Preparation of Special Processed Ginseng
문헌의 방법(김 등, Journal of Natural Products, 63권, 1702-1704쪽, 2000년; 권 등, Journal of Chromatography A, 921권, 335-339쪽, 2001년)에 의하여 특수가공인삼을 제조하였다. Special processed ginseng was prepared by the method of the literature (Kim et al., Journal of Natural Products, Vol. 63, pp. 1702-1704, 2000; Vol., Et al., Journal of Chromatography A, Vol. 921, pp. 335-339, 2001). .
1kg의 인삼을 가압멸균기에 넣고 120℃에서 3시간동안 수증기를 이용하여 가열하였다. 가열처리한 인삼을 꺼내 50 내지 60℃에서 건조시켜 본 발명의 가공인삼을 제조하였다. 1 kg of ginseng was put into an autoclave and heated using steam at 120 ° C. for 3 hours. Take out the heat-treated ginseng and dried at 50 to 60 ℃ to prepare a processed ginseng of the present invention.
[실시 예 2] 특수가공인삼 추출물의 제조Example 2 Preparation of Special Processed Ginseng Extract
1kg의 특수가공인삼을 70% 에탄올로 3시간동안 3회 환류추출한 후 용매를 날려보내 특수가공인삼 추출물 350g을 얻었다. 1 kg of specially processed ginseng was refluxed three times with 70% ethanol for 3 hours, after which the solvent was blown to obtain 350 g of specially processed ginseng extract.
[실시 예 3] 특수가공인삼 분획물의 제조Example 3 Preparation of Specially Processed Ginseng Fraction
상기 실시 예 2의 추출물 300g을 3 리터의 물에 현탁시키고 에테르로 추출한 후 에테르층을 모아 용매를 날려보내어 에테르분획 30g을 얻고, 남은 수층을 부탄올로 추출하여 부탄올층과 수층으로부터 용매를 날려보내 각각 부탄올분획 130g과 물분획 130g을 얻었다. 300 g of the extract of Example 2 was suspended in 3 liters of water and extracted with ether, the ether layer was collected and the solvent was blown out to obtain an ether fraction 30 g, and the remaining aqueous layer was extracted with butanol to blow off the solvent from the butanol layer and the aqueous layer, respectively. 130 g of butanol fraction and 130 g of water fraction were obtained.
[비교예] 인삼 추출물의 제조Comparative Example Preparation of Ginseng Extract
백삼 1kg을 세절한 후 70% 에탄올로 3시간동안 3회 환류추출한 후 용매를 날려보내 백삼추출물을 310g을 제조하였다.After cutting 1kg of white ginseng and refluxing three times with 70% ethanol for 3 hours, the solvent was blown out to prepare 310 g of white ginseng extract.
[실시예 5] 가공인삼의 진세노사이드 함량 분석Example 5 Ginsenoside Content Analysis of Processed Ginseng
본 발명에 따라 제조된 특수가공인삼과 가공하지 않은 백삼, 그리고 홍삼에 함유된 인삼사포닌 성분을 다음과 같은 방법에 의해 분석하였다.The ginseng saponin components contained in the special processed ginseng, raw white ginseng, and red ginseng prepared according to the present invention were analyzed by the following method.
실시예 1에서 제조한 특수가공인삼을 분쇄기를 이용하여 분말로 분쇄한 후, 각각 1 g을 취하여 50 mL 플라스크에 넣고 70% 에탄올 20 mL 씩으로 3시간, 3회 환류추출하여 추출액을 모았다. 각각의 추출액을 감압으로 증발 농축한 다음 남은 잔 사를 메탄올에 녹여 20 mL로 한 액을 특수가공인삼 검액으로 하였다.The special processed ginseng prepared in Example 1 was pulverized into powder using a grinder, 1 g of each was taken into a 50 mL flask, and refluxed three times for 20 hours with 70 mL of ethanol to collect the extract. Each extract was concentrated by evaporation under reduced pressure, and the residue was dissolved in methanol to make 20 mL.
따로 시중에서 구입한 백삼과 홍삼을 동일한 방법으로 추출하여 각각 백삼과 홍삼 검액으로 하였다. Separately, white ginseng and red ginseng purchased on the market were extracted in the same manner to prepare white and red ginseng samples.
진세노사이드 Rb1과 Rg3 표준액을 대조로 하여 문헌의 방법(권 등, Journal of Chromatography A, 921권, pp 335-339)에 의하여 HPLC로 각각의 사포닌 성분을 분석한 결과는 하기 표 1과 같다. As a result of analyzing each saponin component by HPLC using the ginsenoside Rb1 and Rg3 standard solutions by the method of literature (Kwon et al., Journal of Chromatography A, vol. 921, pp 335-339), the results are shown in Table 1 below.
표 1에 나타난 바와 같이 특수가공인삼의 경우 (Rg3+Rg5+Rk1)의 합이 (Rb1+Rb2+Rc+Rd)의 합보다 함량이 더 높음을 알 수 있다.As shown in Table 1, in the case of specially processed ginseng, the sum of (Rg3 + Rg5 + Rk1) is higher than the sum of (Rb1 + Rb2 + Rc + Rd).
[실험예 1] 항불안효과 측정Experimental Example 1 Anti-Anxiety Effect Measurement
실험동물로 ICR계 수컷 마우스(20-25 g)를 한 군당 10-15 마리를 실험에 사용하였고, 한 cage 당 10 마리씩 온도(22±2℃)와 명암 주기(12시간 light/dark cycle)가 일정하게 유지되는 동물실에서 일정 사육기간 후 실험에 사용하였다. 실험 기간동안 물과 사료는 충분히 공급하였다. 시료는 생리식염수 또는 DMSO에 녹인 후 희석하여 측정 3시간 전에 경구로 투여하였다. ICR-based male mice (20-25 g) were used for the experiment, and 10-15 animals per group were used in the experiment. Ten animals per cage had a temperature (22 ± 2 ° C) and a light / dark cycle (12 hours light / dark cycle). It was used for the experiment after a certain breeding period in the animal room kept constant. Water and feed were adequately supplied during the experiment. Samples were dissolved or dissolved in physiological saline or DMSO and administered orally 3 hours before measurement.
항불안효과는 플러스-미로(plus-maze)를 이용하여 측정하였다. 플러스-미로는 검은 플렉시글라스(plexiglas)로 만들어 졌는데 서로 반대 방향인 두개의 오픈 암(open arm, 30×5 cm)과 클로즈드 암(closed arm, 30×5×15 cm)이 십자형으로 이루어져 있다. 오픈 암에는 난간이 없는 형태이며 클로즈드 암에는 투명한 플렉시글라스로 높이 15 cm로 만들어져 있다. 플러스-미로는 바닥으로부터 38 cm 높이 위에 놓고 실험에 사용하였다. Anti-anxiety effect was measured using a plus-maze. The plus-maze is made of black plexiglas, with two open arms (30 × 5 cm) and closed arms (30 × 5 × 15 cm) in opposite directions. The open arm has no railings and the closed arm is made of transparent plexiglass, 15 cm high. The plus-maze was placed 38 cm high from the bottom and used for the experiment.
실험은 마우스가 오픈 암을 바라보면서 미로 중앙에서 자유롭게 돌아다니게 했다. 모든 테스트 과정을 미로에 수직으로 비디오 카메라를 설치하고 녹화하였다. 5분 동안 오픈 암과 클로즈드 암 속으로 각각 출입하는 횟수와 오픈 암 속에서 체재한 시간을 측정 기록하였다. 플러스-미로에서 보낸 전체 시간(300초)에 대한 오픈 암에서 보낸 측정시간을 백분율로 표시하였다. 이 모든 실험은 방음 설치가 되어있는 조용한 환경과 낮은 조도 (50 Lux)에서 13:30-16:30 사이에 실행되었다. 출입(entry)은 네발이 모두 오픈 또는 클로즈드 암에 들어가 있을 때를 말한다. The experiment allowed the mouse to roam freely in the middle of the maze, looking at the open arms. All test procedures were recorded and recorded with a video camera perpendicular to the maze. For 5 minutes, the number of times of entry into the open and closed arms and the length of stay in the open arm were measured and recorded. The measurement time spent in open arms relative to the total time spent in the plus-maze (300 seconds) was expressed as a percentage. All these experiments were carried out between 13: 30-16: 30 in a quiet environment with low noise (50 Lux). Entry is when all four feet are in an open or closed arm.
유의성 검정은 스튜던트 t-테스트(Student's t-test) 통계처리법을 이용하였다. Significance test used Student's t-test statistical method.
백삼과 특수가공인삼 추출물을 각각 50 mg/kg의 용량으로 경구 투여한 결과를 도 1에 나타내었다. 도 1에 나타난 바와 같이 백삼투여군은 생리식염수만 투여한 대조군에 비하여 증가하는 경향은 있었으나 유의성은 없었다. 그러나 특수가공인삼 투여군은 대조군이나 백삼 투여군에 비하여 오픈 암 출입이 유의성있게 훨씬 증가하는 것으로 나타났다. 또한 도 2에 나타난 바와 같이 오픈 암에 머문 시간도 특수가공인삼 투여군이 매우 유의성 있게 증가된 것을 확인 할 수 있었다. 이를 통하여 특수가공인삼이 강력한 항불안 효과가 있음을 알 수 있었다.Oral administration of white ginseng and specially processed ginseng extract at a dose of 50 mg / kg is shown in FIG. 1. As shown in Figure 1, the white ginseng administration group tended to increase compared to the control group administered only saline, but there was no significance. However, the special ginseng group showed significantly higher open cancer access than the control group or white ginseng group. In addition, as shown in FIG. 2, the time spent in open cancer was also significantly increased in the group treated with special ginseng. Through this, special processed ginseng showed strong anti-anxiety effect.
한편 특수가공인삼의 에테르분획, 물분획, 부탄올분획을 각각 25 mg/kg 용량으로 경구 투여한 결과, 도 3과 도 4에 나타난 바와 같이 에테르분획과 물분획에서는 유의성 있는 효과가 나타나지 않았다. 그러나 부탄올분획에서는 매우 유의성 있는 항불안 효과가 나타남을 알 수 있었다. 이 부탄올 분획은 진세노사이드 (20S)Rg3, (20R)Rg3, Rg5, Rk1이 주성분이다.On the other hand, oral administration of the ether fraction, water fraction, and butanol fraction of specially processed ginseng at 25 mg / kg dose, respectively, showed no significant effect in the ether fraction and water fraction as shown in FIGS. 3 and 4. However, the butanol fraction showed a significant anti-anxiety effect. This butanol fraction is composed mainly of ginsenosides (20S) Rg3, (20R) Rg3, Rg5 and Rk1.
이를 통하여 인삼을 특수 가공하여 진세노사이드 Rg3, Rg5, Rk1의 함량의 합이 진세노사이드, Rb1, Rb2, Rc, Rd의 함량의 합보다 더 크게 만든 특수가공인삼이 강력한 항불안 효과가 있으며, 특히 사포닌이 주로 함유되어 있는 부탄올분획에 항불안 활성성분이 함유되어 있음을 알 수 있었다.Specially processed ginseng is made by specially processing ginseng and the sum of the contents of ginsenosides Rg3, Rg5, and Rk1 is greater than the sum of the contents of ginsenosides, Rb1, Rb2, Rc, and Rd. In particular, it was found that butanol fraction mainly containing saponin contained anti-anxiety active ingredient.
본 발명의 가공인삼 추출물은 아래와 같은 제형으로 투여할 수 있으며, 아래의 제제 실시예는 본 발명을 예시하는 것일 뿐, 이에 의해 본 발명의 내용이 제한되는 것은 아니다.The processed ginseng extract of the present invention may be administered in the following formulations, and the following formulation examples are merely to illustrate the present invention, thereby not limiting the contents of the present invention.
제제예 1. 정제의 제조Formulation Example 1 Preparation of Tablet
실시예 3의 가공인삼 추출물..................200㎎Processed ginseng extract of Example 3 ............ 200 mg
유당........................................100㎎Lactose 100 mg
전분........................................100㎎Starch .............................. 100 mg
스테아린산 마그네슘.........................적량Magnesium Stearate ...............
상기의 성분을 혼합하고 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.The above components are mixed and tableted according to a conventional method for producing tablets to produce tablets.
제제예 2. 캡슐제의 제조Formulation Example 2 Preparation of Capsule
실시예 4의 가공인삼추출물...................100㎎Processed Ginseng Extract of Example 4 ... 100 mg
유당........................................50㎎Lactose 50 mg
전분........................................50㎎Starch ........................................ 50 mg
탈크........................................2㎎Talc ........................................ 2mg
스테아린산 마그네슘.........................적량Magnesium Stearate ...............
상기의 성분을 혼합하고 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.Capsules are prepared by mixing the above ingredients and filling into gelatin capsules according to a conventional method for preparing capsules.
제제예 3. 액제의 제조Formulation Example 3 Preparation of Liquid
실시예 3의 가공인삼추출물...................1000㎎Processed Ginseng Extract of Example 3 ................................... 1000 mg
설탕........................................20gSugar ........................................ 20g
이성화당....................................20gIsomerized sugar ......................................... 20g
레몬향......................................적량Lemon Flavor ......................
정제수를 가하여 전체 1000㎖로 맞추었다. Purified water was added to make a total of 1000 ml.
통상의 액제의 제조방법에 따라 상기의 성분을 혼합한 다음, 갈색병에 충전 하고 멸균시켜 액제를 제조한다.According to the conventional method for preparing a liquid, the above components are mixed, and then filled into a brown bottle and sterilized to prepare a liquid.
제제예 4. 건강 식품의 제조Formulation Example 4 Preparation of Healthy Food
실시예 3의 가공인삼추출물...................1000 ㎎Processed Ginseng Extract of Example 3 ...................................... 1000 mg
비타민 혼합물...............................적량Vitamin Blend ...............
비타민 A 아세테이트.................70 ㎍Vitamin A Acetate ......... 70 μg
비타민 E............................1.0 ㎎Vitamin E ............ 1.0 mg
비타민 B1...........................0.13 ㎎Vitamin B1 ........................ 0.13 mg
비타민 B2...........................0.15 ㎎Vitamin B2 ........................ 0.15 mg
비타민 B6...........................0.5 ㎎Vitamin B6 ............... 0.5 mg
비타민 B12..........................0.2 ㎍Vitamin B12 ............... 0.2 μg
비타민 C............................10 ㎎Vitamin C ............ 10 mg
비오틴..............................10 ㎍Biotin .............................. 10 ㎍
니코틴산아미드......................1.7 ㎎Nicotinamide ......... 1.7 mg
엽산................................50 ㎍Folic acid ......................... 50 μg
판토텐산 칼슘.......................0.5 ㎎Calcium Pantothenate ......... 0.5 mg
무기질 혼합물...............................적량Inorganic mixtures ...............
황산제1철...........................1.75 ㎎Ferrous Sulfate ............... 1.75 mg
산화아연............................0.82 ㎎Zinc Oxide ............... 0.82 mg
탄산마그네슘........................25.3 ㎎Magnesium Carbonate ............... 25.3 mg
제1인산칼륨.........................15 ㎎Potassium monophosphate ......................................... 15 mg
제2인산칼슘.........................55 ㎎Dibasic calcium phosphate ............... 55 mg
구연산칼륨..........................90 ㎎Potassium Citrate ............... 90 mg
탄산칼슘............................100 ㎎Calcium Carbonate ... 100 mg
염화마그네슘........................24.8 ㎎Magnesium Chloride ........................... 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.
제제예 5. 건강 음료의 제조Formulation Example 5 Preparation of Healthy Drink
실시예 4의 가공인삼 추출물..................1000 ㎎The processed ginseng extract of Example 4 .. 1000 mg
구연산......................................1000 ㎎Citric Acid .................................... 1000 mg
올리고당....................................100 gOligosaccharide ......................................... 100 g
매실농축액..................................2 gPlum concentrate ........................... 2 g
타우린......................................1 gTaurine ......................................... 1 g
정제수를 가하여 전체........................900 ㎖Purified water is added to the whole ..... 900 ㎖
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. After mixing the above components in accordance with a conventional healthy beverage production method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, use purpose.
본 발명에 의한 특수가공인삼은 인삼에 일체의 화학약품을 섞지 않고 제조하므로, 부작용이나 독성이 없어 안심하고 불안제, 항우울제, 또는 항스트레스제로 사용할 수 있다.
The special processed ginseng according to the present invention is manufactured without mixing any chemicals with ginseng, so it can be used as an anxiety agent, antidepressant, or antistress agent with no side effects or toxicity.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030070249A KR100555653B1 (en) | 2003-10-09 | 2003-10-09 | Composition comprising an extract of processed Panax genus plant for preventing and treating anxiety |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030070249A KR100555653B1 (en) | 2003-10-09 | 2003-10-09 | Composition comprising an extract of processed Panax genus plant for preventing and treating anxiety |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050034354A KR20050034354A (en) | 2005-04-14 |
KR100555653B1 true KR100555653B1 (en) | 2006-03-03 |
Family
ID=37238247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030070249A KR100555653B1 (en) | 2003-10-09 | 2003-10-09 | Composition comprising an extract of processed Panax genus plant for preventing and treating anxiety |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100555653B1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100665087B1 (en) * | 2004-12-07 | 2007-01-04 | 주식회사 진생사이언스 | Composition comprising ginsenoside Rg5 and Rk1 for improving brain function and memory dysfunction |
CN100438876C (en) | 2006-06-09 | 2008-12-03 | 上海中药创新研究中心 | Use of 20(S)-protopanoxadiol in preparation of antidepressant medicine |
KR101375483B1 (en) * | 2011-12-26 | 2014-03-17 | 고성권 | Ginseng prosapogenin high concentration containing Sanchi ginseng preparation using sonication and process for thereof |
-
2003
- 2003-10-09 KR KR1020030070249A patent/KR100555653B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20050034354A (en) | 2005-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100425022B1 (en) | Ginseng extract and pharmaceutical composition containing it | |
KR101392204B1 (en) | Composition comprising herbal extract of red ginseng, Angelicae gigantis Radix, citrus peel and green tea leaves for treating or preventing vascular diseases | |
KR20070040209A (en) | Composition comprising the fraction of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction | |
KR100730302B1 (en) | Composition comprising the extract of Cassiae Semen for treating or preventing cognitive dysfunction | |
KR100524385B1 (en) | Composition comprising the extracts of Longanae arillus, Zizyphi spinosae semen, Polygalae radix and Poria cocos for the enhancement of memory and the improvement of juvenile learning | |
KR100824970B1 (en) | Polygoni cuspidati radix extract for allergic disease and process for preparation thereof | |
CN106581115B (en) | Composition containing yuankanin and ginseng and application thereof | |
KR100522579B1 (en) | Pharmaceutical composition comprising the extracts of scutellaria root and schizandra fruit mixture thereof having an effect of restraint stress | |
JP6762946B2 (en) | Compositions for the prevention, amelioration, or treatment of burnout syndrome | |
KR100646595B1 (en) | Pharmaceutical composition comprising the extract of Bamboo leaf for treating and preventing the mental disease related to cranial nervous system | |
KR100555653B1 (en) | Composition comprising an extract of processed Panax genus plant for preventing and treating anxiety | |
KR100867612B1 (en) | Composition comprising sungnoiwon for improving brain function and memory dysfunction | |
KR20080008929A (en) | Health care food composition comprising oroxylin a for preventing or improving cognitive dysfunction | |
KR100462788B1 (en) | Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory | |
KR20110075496A (en) | Composition comprising the extract of prunella vulgaris l for preventing and treating schizophrenia and amnesia | |
KR100471340B1 (en) | A new process for enhancing the efficacies of Ginseng | |
KR20030080296A (en) | Composition containing saponin fraction and derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease | |
KR101367885B1 (en) | A composition comprising the extract of combined herb of Panax ginseng and Vitis genus plant treating and preventing neuro-degenerative disease and enhancing memory power | |
KR20100089910A (en) | Composition comprising the mixed herbal extract for preventing and treating hyperlipidemia and diabetic hyperlipidemia | |
KR100638344B1 (en) | Composition comprising the crude drug extract for improving eye symptoms of VDT syndrome | |
KR100453542B1 (en) | Food additive and health foods containing Ginseng extract | |
KR102372942B1 (en) | Pharmaceutical composition comprising the non-oil fraction of seed extract of panax ginseng c. a. meyer as an effective component for prevention or treatment of diabetes and health functional food comprising the same | |
KR20060030575A (en) | Pharmaceutical composition comprising the complex crude drug extract for preventing and treating hyperthyroidism | |
KR20040041235A (en) | Pharmaceutical composition comprising the water-soluble component of kupferkies and the extract of crude drug effective to treat neuronal paralysis and neuralgia | |
KR100881368B1 (en) | Composition comprising mixed herbal extract for preventing and treating depression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130220 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140221 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150225 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160217 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170217 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190102 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20191231 Year of fee payment: 15 |